Xu Z - Search Results

1

Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases.

Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L, Zhu T. Jin K, et al. Among authors: xu z. PLoS One. 2011;6(12):e28384. doi: 10.1371/journal.pone.0028384. Epub 2011 Dec 2. PLoS One. 2011. PMID: 22164281 Free PMC article.

2

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Jin K, et al. Among authors: xu z. Clin Transl Oncol. 2010 Jul;12(7):473-80. doi: 10.1007/s12094-010-0540-6. Clin Transl Oncol. 2010. PMID: 20615824 Review.

3

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Jin K, He K, Han N, Li G, Wang H, Xu Z, Jiang H, Zhang J, Teng L. Jin K, et al. Among authors: xu z. Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1814-22. doi: 10.5754/hge11136. Epub 2011 Jul 15. Hepatogastroenterology. 2011. PMID: 21940303

4

Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.

Jin K, Lan H, Cao F, Han N, Xu Z, Li G, He K, Teng L. Jin K, et al. Among authors: xu z. Int J Oncol. 2012 Aug;41(2):583-8. doi: 10.3892/ijo.2012.1469. Epub 2012 May 10. Int J Oncol. 2012. PMID: 22581265

5

Antitumor effects of FP3 in combination with capecitabine on PDTT xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.

Jin K, Lan H, Xie B, He K, Xu Z, Li G, Han N, Teng L, Cao F. Jin K, et al. Among authors: xu z. Cancer Biol Ther. 2012 Jul;13(9):737-44. doi: 10.4161/cbt.20556. Epub 2012 May 23. Cancer Biol Ther. 2012. PMID: 22617773 Free article.

6

Antitumor effect of FP3 in a patient-derived tumor tissue xenograft model of gastric carcinoma through an antiangiogenic mechanism.

Jin K, Lan H, Cao F, Xu Z, Han N, Li G, He K, Teng L. Jin K, et al. Among authors: xu z. Oncol Lett. 2012 May;3(5):1052-1058. doi: 10.3892/ol.2012.603. Epub 2012 Feb 10. Oncol Lett. 2012. PMID: 22783390 Free PMC article.

7

Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?

Jin K, Shen Y, He K, Xu Z, Li G, Teng L. Jin K, et al. Among authors: xu z. Clin Transl Oncol. 2010 Aug;12(8):526-32. doi: 10.1007/s12094-010-0550-4. Clin Transl Oncol. 2010. PMID: 20709650 Review.

8

Antitumor effect of FP3 on a patient-derived tumor tissue xenograft model of rectal carcinoma.

Bi T, Bi T, Lan H, Hu X, Zhu M, Xu Z, Hu J, Teng L, Jin K. Bi T, et al. Among authors: xu z. Hepatogastroenterology. 2013 Nov-Dec;60(128):1950-4. Hepatogastroenterology. 2013. PMID: 24719933

9

Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?

Jin K, He K, Teng F, Han N, Li G, Xu Z, Teng L. Jin K, et al. Among authors: xu z. Per Med. 2011 Mar;8(2):175-182. doi: 10.2217/pme.10.81. Per Med. 2011. PMID: 29783410

10

COL12A1, a novel potential prognostic factor and therapeutic target in gastric cancer.

Jiang X, Wu M, Xu X, Zhang L, Huang Y, Xu Z, He K, Wang H, Wang H, Teng L. Jiang X, et al. Among authors: xu x, xu z. Mol Med Rep. 2019 Oct;20(4):3103-3112. doi: 10.3892/mmr.2019.10548. Epub 2019 Aug 1. Mol Med Rep. 2019. PMID: 31432110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39,069 results

Search Page

Filters